Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Vericel Corporation (VCEL)

Biological Products, (no Disgnostic Substances)

https://www.vcel.com

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

64 SIDNEY ST.
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/04/1997

Market Cap

2,299,222,199

Shares Outstanding

47,730,000

Weighted SO

47,724,543

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

CLGN --.--%

KROS --.--%

MRUS --.--%

IPSC --.--%

CMRX --.--%

DAWN --.--%

XFOR --.--%

MREO --.--%

TERN --.--%

Beta

1.7040

Last Div

0.0000

Range

30.18-54.09

Chg

0.7540

Avg Vol

369475

Mkt Cap

2299222199

Exch

NASDAQ

Country

US

Phone

617 588 5555

DCF Diff

42.2177

DCF

3.9223

Div Yield

0.0000

P/S

10.7180

EV Multiple

948.9191

P/FV

9.3963

Div Yield %

0.0000

P/E

2893.6391

PEG

204.6752

Payout

0.0000

Current Ratio

4.5001

Quick Ratio

4.1607

Cash Ratio

1.7293

DSO

81.6639

DIO

85.6384

Op Cycle

167.3023

DPO

145.0566

CCC

22.2457

Gross Margin

0.7042

Op Margin

-0.0178

Pretax Margin

0.0075

Net Margin

0.0037

Eff Tax Rate

1.3404

ROA

0.0021

ROE

0.0035

ROCE

-0.0115

NI/EBT

0.4922

EBT/EBIT

-0.4195

EBIT/Rev

-0.0178

Debt Ratio

0.2537

D/E

0.3934

LT Debt/Cap

0.2699

Total Debt/Cap

0.2823

Int Coverage

-12.4869

CF/Debt

0.4497

Equity Multi

1.5509

Rec Turnover

4.4695

Pay Turnover

2.5163

Inv Turnover

4.2621

FA Turnover

1.4682

Asset Turnover

0.5693

OCF/Share

0.8830

FCF/Share

-0.0450

Cash/Share

2.6306

OCF/Sales

0.2004

FCF/OCF

-0.0509

CF Coverage

0.4497

ST Coverage

7.4239

CapEx Coverage

0.9515

Div&CapEx Cov

0.9515

P/BV

9.3963

P/B

9.3963

P/S

10.7180

P/E

2893.6391

P/FCF

-1049.8732

P/OCF

53.1048

P/CF

53.1048

PEG

204.6752

P/S

10.7180

EV Multiple

948.9191

P/FV

9.3963

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 30, 06:00 Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06% GlobeNewswire Inc. Jan 09, 07:55 Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results GlobeNewswire Inc. Nov 08, 07:55 Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance GlobeNewswire Inc. Nov 07, 08:30 Vericel to Present at the Stephens Annual Investment Conference GlobeNewswire Inc. Oct 25, 08:30 Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023

Revenue Product Segmentation